Avelumab in Combination with Axitinib as First-Line Treatment in Patients with Advanced Hepatocellular Carcinoma: Results from the Phase 1b VEGF Liver 100 Trial.

Kudo, Masatoshi; Motomura, Kenta; Wada, Yoshiyuki; Inaba, Yoshitaka; Sakamoto, Yasunari; Kurosaki, Masayuki; Umeyama, Yoshiko; Kamei, Yoichi; Yoshimitsu, Junichiro; Fujii, Yosuke; Aizawa, Mana; Robbins, Paul B; Furuse, Junji

Kudo, Masatoshi; Motomura, Kenta; Wada, Yoshiyuki; Inaba, Yoshitaka; Sakamoto, Yasunari; Kurosaki, Masayuki; Umeyama, Yoshiko; Kamei, Yoichi; Yoshimitsu, Junichiro; Fujii, Yosuke; Aizawa, Mana; Robbins, Paul B; Furuse, Junji.

Afiliación

Kudo M; Faculty of Medicine, Kindai University, Osaka, Japan.
Motomura K; Aso Iizuka Hospital, Fukuoka, Japan.
Wada Y; Kyushu Medical Center, Fukuoka, Japan.
Inaba Y; Aichi Cancer Center Hospital, Nagoya, Japan.
Sakamoto Y; National Cancer Center Hospital, Tokyo, Japan.
Kurosaki M; Musashino Red Cross Hospital, Tokyo, Japan.
Umeyama Y; Pfizer R&D Japan, Tokyo, Japan.
Kamei Y; Pfizer R&D Japan, Tokyo, Japan.
Yoshimitsu J; Pfizer R&D Japan, Tokyo, Japan.
Fujii Y; Pfizer R&D Japan, Tokyo, Japan.
Aizawa M; Pfizer R&D Japan, Tokyo, Japan.
Robbins PB; Pfizer, San Diego, California, USA.
Furuse J; Faculty of Medicine, Kyorin University, Tokyo, Japan.

Liver Cancer ; 10(3): 249-259, 2021 Jun.

Article en En | MEDLINE | ID: mdl-34239811

Palabras clave

Avelumab; Axitinib; Hepatocellular carcinoma; Immune checkpoint inhibitor; Vascular endothelial growth factor receptor tyrosine kinase inhibitor

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Idioma: En Revista: Liver Cancer Año: 2021 Tipo del documento: Article País de afiliación: Japón

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Idioma: En Revista: Liver Cancer Año: 2021 Tipo del documento: Article País de afiliación: Japón